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CLINICAL RELEVANCY STATEMENT 
In an elective surgical population, the provision of pharmaconutrition containing 
supraphysiological doses of arginine, with or without glutamine, omega-3 fatty acids, and 
nucleotides has been theorized to modulate the immune and metabolic responses. 
Therefore pharmaconutrition may improve clinical outcomes such as posteroperative 
infective complications and length of hospital stay (LOS) without adversely affecting 
mortality. However the results of a number of randomized controlled trials (RCTs) have been 
conflicting. This meta-analysis appears to confirm the commonly accepted benefits of 
arginine-dominant pharmaconutrition in relation to reductions in postoperative infective 
complications and LOS.  Nonetheless these benefits were only seen in peri- and 
postoperative pharmaconutrition administration in the current work. It is therefore evident 
that the timing of pharmaconutrition provision is of utmost importance and this information is 
necessary to guide clinical practice and institutional policy. The current work differs from 
previous meta-analyses through the emphasis on timing of pharmaconutrition provision, use 
of stricter inclusion criteria to reduce heterogeneity in the results obtained, and by including 
the latest available publications. 
 
STRUCTURED ABSTRACT 
Background: Pharmaconutrition has previously been reported in elective surgery to reduce 
postoperative infective complications and duration of hospital length of stay. 
Objective: To update previously published meta-analyses and elucidate potential benefits of 
providing arginine-dominant pharmaconutrition in surgical patients specifically with regard to 
the timing of administration of pharmaconutrition.  
Design: RCTs comparing the use of pharmaconutrition with standard nutrition in elective 
adult surgical patients between 1980 and 2011 were identified. The meta-analysis was 
prepared in accordance with PRISMA recommendations.  
Results: Twenty studies yielding twenty-one sets of data met inclusion criteria. A total of 
2005 patients were represented (pharmaconutrition n = 1010; control n = 995), in whom 
pharmaconutrition was provided preoperatively (k = 5), perioperatively (k = 2) or 
postoperatively (k =14). No differences were seen in postoperative mortality with the 
provision of pharmaconutrition irrespective of timing of administration. Statistically significant 
reductions in infectious complications and LOS were found with perioperative and 
postoperative administration. Perioperative administration was also associated with a 
statistically significant reduction in anastomotic dehiscence while a reduction in non-infective 
complications was demonstrated with postoperative administration. Preoperative 
pharmaconutrition demonstrated no notable advantage over standard nutritional provision in 
any of the clinical outcomes assessed.  
Conclusions: This meta-analysis highlights the importance of timing as a clinical 
consideration in the provision of pharmaconutrition in elective gastrointestinal surgical 
patients and identifies areas of where further research is required. 
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INTRODUCTION 
Nutrition provision is recognized to be an important aspect in the perioperative management 
of elective gastrointestinal surgery patients, and the timely provision of nutrition has been 
associated with improved postoperative outcomes1, 2. The benefits of nutritional provision in 
surgical patients are traditionally thought to arise from the provision of macronutrients such 
as calories for energy and protein for wound healing, and to reduce the impact of catabolism 
in the postoperative period. However, it has been theorized that due to the complex 
inflammatory, immune and oxidative stress that is experienced postoperatively, providing 
specific nutrients in supraphysiological doses may provide vital substrates that serve to 
modulate these immune and metabolic responses and thus improve clinical outcomes3. In 
view of this, during the early 1990s new nutrition support formulas emerged containing 
higher quantities of arginine, with or without glutamine, omega-3 fatty acids, and 
nucleotides3. These products have been commonly referred to as ‘immunonutrition’, 
‘immune-enhancing diets’, and more recently as ‘pharmaconutrition’ in recognition of their 
intended pharmaceutical-like action rather than purely as nutrient provision3. 
 
In an elective surgical population, the use of pharmaconutrition has been reported to reduce 
postoperative infective complications and LOS, without adversely affecting mortality 
described in medical and trauma subgroups of a critically ill population4-10. The results of 
individual studies have been conflicting11-15, however the use of these products gain 
increasing acceptance following their incorporation into practice guidelines16, 17. Seven meta-
analyses on this topic have been conducted on surgical patients18-21 or with surgical patients 
as a subgroup analysis of a critical care population22-24, however there are limitations to 
applying the outcomes of these meta-analyses to practice due to the inclusion of studies 
utilizing non-equivalent control groups, inclusion of diverse surgical populations, and the 
failure to account for practical differences between the studies (i.e. administration protocols 
of pharmaconutrition).  
  
The objective of the current work is to further explore the literature describing the 
postoperative outcomes from RCTs comparing the timing of provision of arginine-dominant 
pharmaconutrition formulations with standard products in an elective gastrointestinal surgery 
population. The timing of pharmaconutrition provision is considered of the utmost importance 
as this information is necessary to guide clinical practice and institutional policy. The current 
work differs from previous meta-analyses through the emphasis on timing of 
pharmaconutrition provision, use of stricter inclusion criteria to reduce heterogeneity in the 
results obtained, and by including the latest available publications.   
 
MATERIALS AND METHODS 
Inclusion and Exclusion Criteria 
Studies comparing the provision of arginine-dominant (>9g Arg/L) pharmaconutritional 
formulations with or without other immune-modulating nutrients to those of standard 
nutritional composition were reviewed. Only RCTs with primary comparisons between the 
different nutritional formulations were considered for inclusion. For inclusion, studies must 
also have been conducted in adult (>18 years) elective gastrointestinal surgical patients, and 
have reported on clinically relevant outcomes pertaining to the postoperative period. 
Outcomes assessed were those considered to exert influence over practical aspects of 
surgical practice and institutional policy decisions. All studies reporting on outcomes of this 
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nature were considered and final analyses were run on outcome variables where numbers 
were sufficient to allow statistical analysis.  
 
Additional exclusion criteria included studies that investigated the effect of parenteral 
provision supplemented with pharmaconutrients, and duplicate publications.  
 
Search Strategies and Data Collection 
Electronic databases (Medline, Pubmed, EMBASE, CINAHL, Cochrane Register of 
Systematic Reviews, Science Citation Index) were cross-searched for RCTs published 
between 1980 and 2011, using search terms customized to each search engine in an 
attempt to detect published papers meeting the inclusion criteria. Limits were set to RCTs 
and adult patients to reflect the inclusion criteria. Search strategies utilized included 
(IMMUNONUTRITON and SURGERY), (IMMUN* and NUTRITION), 
(PHARMACONUTRITION), (ARGININE or OMEGA-3 or RNA or NUCLEOTIDE and 
SURGERY). Reference lists of reviews and existing meta-analyses were hand searched for 
further appropriate citations. Companies that produce pharmaconutrition products and 
experts in the field were contacted for information about unpublished studies. Where 
necessary, authors were contacted by e-mail (and follow-up letter by post where a response 
to a second e-mail was not received) for clarification or additional information.  
 
The data were prepared in accordance with the Preferred Reporting of Systematic Reviews 
and Meta-Analyses (PRISMA) statement25. Data extraction and critical appraisal of identified 
studies were carried out by two authors (EO and MAM) for compliance with inclusion criteria. 
The authors were not blinded to the source of the document or authorship for the purpose of 
data extraction. The data were compared and discrepancies were addressed with discussion 
until consensus was achieved.  
 
Evaluation of methodological quality of identified studies was conducted using the Jadad 
scoring system which provides a numerical quality score based on the reporting of 
randomization, blinding and reporting of withdrawals26. 
 
Statistical Analysis 
Meta-analyses were performed using odds ratios (ORs) for binary outcomes and weighted 
mean differences (WMDs) for continuous outcome measures. A slightly amended estimator 
of OR was used to avoid the computation of reciprocal of zeros among observed values in 
the calculation of the original OR27. Random effects models, developed by using the inverse 
variance weighted method approach28, were used to combine the data. Heterogeneity 
among the study measures was assessed using the Q statistic28-30 and I2 index31, 32. 
 
Sensitivity analyses were conducted by removing studies that utilized experimental 
formulations with considerable differences in their product formulation to assess their 
influence on the results obtained. 
 
Funnel plots were synthesized in order to determine the presence of publication bias in the 
meta-analysis. Standard error was plotted against the treatment effects (Log OR for the 
dichotomous and WMD for continuous variables respectively)28, 33, 34 to allow 95% confidence 
interval limits to be displayed.  All estimates were obtained using computer programs written 
in R35. All plots were obtained using the ‘rmeta’ package36.  
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A significance level of 5% ( =0.05) was applied to tests of hypotheses. 
 
RESULTS 
Included studies 
Cross searching of electronic databases yielded a total of 211 abstracts and hand searches 
of reference lists provided a further 16 citations. After exclusion of 136 duplicate citations, 91 
unique citations of potential relevance were retrieved for review. The process by which these 
were excluded from inclusion is described in Figure 1. Two potentially relevant studies37, 38 
were unable to be assessed due to lack of access to the non-English language journals in 
which they were published. While a further potentially relevant unpublished study (‘Sydney’) 
was identified through a citation search of a previous published meta-analysis18, attempts to 
contact authors and the company manufacturing the product did not yield any additional 
information; therefore the study could not be assessed for inclusion. Correspondence with 
the companies producing commercially available pharmaconutrition products did not yield 
additional unpublished studies, however the plans for an upcoming RCT were obtained 
through correspondence with an author of the Waitzberg et al18 meta-analysis.  
 
The twenty studies that met the inclusion criteria are described in Tables 1 to 4, however 
due to multiple arms of single studies independently meeting the inclusion criteria in one 
study12 there were twenty-one individual sets of data analyzed. For eligible studies that 
incorporated multiple intervention arms in their study design, only those that utilized the 
enteral route were included in the analysis. Pooled results yielded 2005 patients (n=1010 
pharmaconutrition; n=995 control) from studies published between 1988 and 2011. Studies 
were categorized according to the timing of pharmaconutrition provision: four studies, 
yielding five sets of data, provided preoperative interventions (pharmaconutrition provided 
five to seven days preoperatively as oral supplement), fourteen studies described 
postoperative interventions (pharmaconutrition product commenced via jejunal feeding tube 
on Postoperative Day (POD) 1 or 2, used to meet a defined nutritional goal until POD7 or 
when oral intake was established); and two studies provided perioperative interventions 
(providing both pre- and postoperative provision of pharmaconutrition as described above). 
 
The included studies collectively demonstrate moderate methodological quality according to 
the Jadad score with an average score of 3.1 (out of five), with a range of one to five. 
Fourteen studies reported on withdrawals4, 5, 9, 11-15, 39-44, thirteen described an appropriate 
method of randomization4-7, 9, 13, 14, 39-42, 45, 46, and eight studies reported utilizing blinding5, 9, 12, 
42, 44, 47. One study was not included in the eight that reported using a blinded method, as 
although it states it was a double-blind methodology in the title, this was not referred to 
throughout the article40. Jadad scores are reported in Tables 2 to 4. 
 
All but seventeen patients (fourteen from Jiang et al43, two from Sodergren45 and one from 
Daly et al47 representing <1% of the total patients analyzed) received elective surgery for the 
curative management of gastrointestinal malignancies (see Table 4). Twelve studies 
reported on the rates of malnutrition within their study population4-7, 9, 12-15, 40, 41, 47: Rates 
varied greatly, ranging from 9% to 100% with an average of about 40%. Malnutrition was 
defined as ≥10% body weight loss in most studies.  
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The nutritional composition products utilized in the included studies are summarized in 
Tables 5 and 6. All but three studies used commercially available pharmaconutrition 
products of similar composition (that is, Arginine 9-12g/L, with omega-3 fatty acids and 
nucleotides): Impact® or Oral Impact® account for 65% of the studied products. The 
experimental products used by McCarter et al12 and Daly et al47 were of significantly different 
composition (higher arginine (26g/L) content, with or without glutamine or omega-3 fatty 
acids). The Sodergren et al45 study product was reported to be a prototype of Intestamin® 
that contains arginine, glutamine, omega-3 fatty acids, and micronutrients, however the 
exact composition of the product could not be ascertained due to it being subject to 
‘commercial in confidence’ conditions (personal communication). The authors’ [EO and 
MAM] interpretation of the nature of the feeding regimen for the prototype product suggests 
a composition more similar to the existing pharmaconutrition products used in a surgical 
population than to the commercially available Intestamin® product48, it was therefore 
included in the meta-analysis but omitted for sensitivity analyses.  
 
Thirteen of the twenty studies included stated they received support from the companies that 
produce the products being studied4-7, 9, 11, 12, 39, 41, 42, 44, 45, 47. Support was most commonly 
received through the provision of pharmaconutrition products, and occasionally though direct 
financial support. Other studies are unclear about the nature of company involvement14, 15, 43, 
46, 49, and only two studies deny any conflict of interest or financial support13, 40.  
 
 
 
 
Clinical Outcomes 
Sufficient data were available for the analysis for six clinically relevant outcomes: in-hospital 
mortality; infective complications; anastomotic dehiscence; non-infectious complications; 
LOS; and gastrointestinal tolerance.  
 
Statistically significant reductions in infectious complications and LOS were found with 
perioperative and postoperative administration of pharmaconutrition (OR 0.44, 95% CI 0.24, 
0.81, p=0.001; WMD -2.57, 95% CI -3.70, -1.44, p=0.001 and OR 0.61, 95% CI 0.47, 0.79, 
p<0.01; WMD -2.30, 95% CI -3.71, -0.89, p=0.001 respectively). Perioperative administration 
was also associated with a statistically significant reduction in anastomotic dehiscence (OR 
0.39, 95% CI 0.17, 0.93, p=0.03), while a reduction in non-infective complications was 
demonstrated with postoperative administration of pharmaconutrition (OR 0.70, 95% CI 0.52, 
0.94, p=0.02).  No significant difference in mortality was demonstrated irrespective of timing 
of pharmaconutrition. Preoperative pharmaconutrition demonstrated no notable advantage 
over standard nutritional provision in any of the clinical outcomes assessed. Results are 
summarized in Tables 7 to 9 and selected forest plots are presented in Figures 2 to 5. 
 
Omission of studies45, 47 using non-commercially available products did not alter the 
outcomes obtained in the sensitivity analyses (data not presented). 
 
Heterogeneity 
In general there was a high degree of accord between the outcomes in the included studies, 
with significant heterogeneity only detected in LOS. The latter was consistent across all 
timings of pharmaconutrition administration for this outcome.  
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Publication Bias 
Funnel plots demonstrate symmetry and thus suggest the absence of publication bias for all 
outcomes except LOS. (Figure 6). 
 
DISCUSSION 
This meta-analysis both confirms previous findings regarding arginine-dominant 
pharmaconutrition and provides further insight into the effects of its use. Firstly it continues 
to show no adverse effect on postoperative mortality in elective gastrointestinal surgical 
populations. It also supports the commonly accepted benefits of arginine-dominant 
pharmaconutrition with relation to reductions in postoperative infective complications, 
however these benefits were only seen in peri- and postoperative pharmaconutrition 
administration in the current work. Similarly, reductions in LOS were noted in peri- and 
postoperative administration, however heterogeneity evidenced by a high I2 index and 
publication bias present in this data makes it difficult to draw concrete conclusions on this 
parameter. 
 
Distinct differences in the attributed benefits of pharmaconutrition and the timing of its 
administration is an important finding of this meta-analysis. Previous meta-analyses 
performing a priori analyses on timing of pharmaconutrition report benefit irrespective of 
when in the clinical course it is provided19, 20. One notable exception is that preoperative 
pharmaconutrition was not shown to reduce LOS by Cerantola et al20. The current work 
demonstrates no benefit from the provision of preoperative pharmaconutrition across any of 
the outcomes assessed. A possible explanation for this is the stricter inclusion criteria 
applied to minimise heterogeneity. Thus the results reported may be a truer indication of the 
effect of preoperative pharmaconutrition in this surgical population. The pharmacokinetics of 
pharmaconutrients may assist in understanding this finding. Serum arginine levels have 
been shown to significantly increase following seven days of preoperative12, 50 and 
postoperative administration41, 51. Sustained elevated serum levels have been demonstrated 
at POD8 with perioperative administration50. However no study appears to have investigated 
the postoperative serum levels of patients receiving preoperative pharmaconutrients as a 
standalone intervention. It is therefore conceivable that the cessation of pharmaconutrition 
on the day of surgery may result in sub-therapeutic or declining levels of circulating 
pharmaconutrients within the postoperative period when their action may be most valuable. 
Beta-error (false negative) may also play a part in the findings reported in this and/or 
previous meta-analyses given the small number of studies investigating preoperative 
pharmaconutrition interventions.  
 
The current work further suggests that pharmaconutrition may provide additional benefits in 
terms of reduction of anastomotic dehiscence and non-infective complications in 
perioperative and postoperative administration respectively – these phenomena have not 
previously been reported in association with arginine-dominant pharmaconutrition. Reduced 
non-infectious complications in postoperative pharmaconutrition provision may potentially be 
explained by the higher caloric and/or nitrogen content of many of the pharmaconutrition 
formulations when compared to the control formulations. Six of the fourteen studies (42%) 
included in the postoperative meta-analysis use intervention products that contain between 
20 and 46% more protein11, 14, 40, 43, 47, 49 and/or up to 600kcal (20%) more energy14 than the 
control formulations. In a gastrointestinal surgical population with a high prevalence of 
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malnutrition, the higher overall nutritional provision may be enough to account for this 
unexpected finding given that malnourished patients experience more profound 
improvements in clinical outcomes attributable to nutritional provision than their well-
nourished counterparts52. This explanation, however, does not adequately explain the 
reduced anastomotic dehiscence reported with the perioperative administration of 
pharmaconutrition as these used comparable products for both arms of their studies. As 
leukocytosis is recognised as a risk factor for anastomotic dehiscence53 it seems plausible 
that the reduction in infective complications associated with pharmaconutrition may provide 
additional protection in the surgical anastomosis through this mechanism. However given the 
small number of perioperative studies analysed (k=2), beta-error may also be a plausible 
explanation for this finding. 
 
Although seven meta-analyses on this topic already exist, there are limitations contained 
within these that justify a further meta-analysis. Heyland et al23, Beale et al24 and Heys et al22 
all include elective surgical patients as a subgroup analysis of meta-analyses on the critically 
ill. While all utilise inclusion criteria comparable to the current work, there have been many 
RCTs eligible for inclusion since their publication. Waitzberg et al18 conducted a meta-
analysis on studies published before 2003 that utilised the commercially available product, 
Impact® [Novartis Consumer Health, Switzerland]. This meta-analysis included cardiac 
surgery with an otherwise largely gastrointestinal surgery population, and included studies 
that utilised non-equivalent control groups such as intravenous fluids or crystalloids, or nil-
by-mouth. The heterogeneity introduced through these inclusions, the exclusion of studies 
conducted using other similarly composed commercial products, and the suggestion that this 
meta-analysis has been funded by Novartis result in the need to interpret the outcomes of 
this analysis with caution.  
 
Zheng et al21 restricts inclusion criteria to gastrointestinal surgery but makes no attempt to 
control for the differences within the administration of pharmaconutrition between studies. 
Furthermore, an additional ten studies have been identified as being published since 2006 
that were not available to be included in this study.  
 
Marik and Zaloga19 compared the effect of arginine and/or omega-3 containing 
pharmaconutrition products with standard formulations, and included a priori analyses on 
differing compositions and timing of pharmaconutrition. Their results are difficult to apply to 
practice, however, due to the heterogeneous surgical populations included (head and neck, 
cardiac, gastrointestinal) and the significant methodological flaw of performing meta-analysis 
statistics in instances where only one study met the inclusion criteria54.  
 
The most recent meta-analysis was published by Cerantola et al20 in 2011. This paper 
incorporated recently published studies on an exclusively gastrointestinal surgical 
population, addressed the timing of pharmaconutrition provision through performing 
subgroup analyses, and is the first meta-analysis on this topic to comply with PRISMA 
reporting guidelines. However, it also includes studies that use non-equivalent control 
groups7, 8, 10, 55: This may produce outcomes that appear to favour pharmaconutrition 
independent of the role of immune-enhancing components. 
 
For these reasons the current work has attempted to contribute to the literature on this topic 
through producing a meta-analysis that utilises stricter inclusion criteria with regards to the 
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control group (as far as the literature allows), and to exclusively analyse studies according to 
the timing of pharmaconutrition delivery. We believe this issue is of vital importance to guide 
the translation of research to clinical practice.  
 
This meta-analysis is not without its limitations. Firstly, there are variations in the 
composition of included pharmaconutrition products that may confound the results obtained. 
The decision to allow inclusion of studies using products containing arginine +/- other 
pharmaconutrients was based on consideration that arginine has been the most consistently 
utilized pharmaconutrient in elective gastrointestinal surgical populations, and remains the 
consistent ingredient that links commercial and experimental formulas in this genre of 
products. Other pharmaconutrients included in the commercially available formulas have 
limited clinical evidence of individual benefit when provided enterally in this patient group in 
the absence of arginine. On this basis we argue that there is clinical relevance to classifying 
the intervention products as ‘arginine-dominant’.   
 
Secondly, while all studies described the nutritional goals for their patients throughout the 
study period, few quantified the amount of nutrition actually received. We have therefore 
been forced to assume that nutrition goals were consistently met unless otherwise stated. 
This has obvious implications for the conclusions drawn, as reduced nutritional provision for 
reasons such as feed intolerance, non-compliance with oral supplements, tube-related 
complications or protocol deviations may have reduced the provision of nutrients and 
therefore may confound the results obtained. This aspect of reporting trials on 
pharmaconutrition need to be addressed in future studies on this topic. 
 
Thirdly, the majority of the pharmaconutrition studies have been funded at least in part by 
the companies that manufacture the products being investigated. This is of concern as 
funding bias is recognised for its potential to influence the results in favour of the product 
being investigated in pharmaceutical studies56, 57. As meta-analysis is known to amplify 
biases included in the individual studies, the concern that funding bias may be present and 
has the potential to exaggerate the beneficial effects of pharmaconutrition should not be 
overlooked: This is true of both the current work and the existing meta-analyses on this 
topic. This is of particular concern given the increasing acceptance that pharmaconutrition 
has found in clinical practice through its incorporation into clinical guidelines16, 17. 
Interestingly, discussion of this aspect of pharmaconutrition is notably absent from the 
literature at the present time. 
  
Closely tied to concerns regarding funding bias is the frequent use of non-comparable 
control groups: this is a commonly observed trend in pharmaceutically funded studies that 
are subsequently shown to favour the intervention product57. Significantly different protein 
contents between some of the intervention and control products were noted in several of the 
included studies. One such example is the Klek et al14 study that uses Peptisorb® [Nutricia 
Ltd, Poland] (40g protein/L; 1kcal/mL) as the control product against Stresson® [Nutricia Ltd, 
Poland] (75g protein/L; 1.25kcal/mL). While the lack of reporting of received nutrition make 
the significance of these differences on the current work impossible to evaluate, even in 
studies that utilise individualized nutritional goals based on caloric targets, such marked 
differences in formulations may ultimately undermine the controlled nature of individual 
studies due to the lack of appropriate control group. 
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We made multiple attempts to contact authors for additional information or clarification of 
data within their publications but with disappointing response rates. In the absence of 
response from the group from Milan, Italy who published many of the papers on this topic in 
the mid-1990s and early 2000s, we excluded any of their studies we strongly suspected of 
representing multiple reports on the same patients58-60. It is clear from the published reports, 
however, that in so doing we have excluded approximately 80 otherwise eligible patients 
with gastric cancer that we could not include without a high likelihood of duplicating analyses 
on patients with pancreatic cancer included in other studies6. 
 
Furthermore, several potentially relevant sources were identified (‘Sydney’ study in 
Waitzberg et al18, Jiang et al38 [in Chinese] and an abstract for Yao et al37 [in Chinese]), 
however adequate data to assess them for inclusion were unavailable despite our best 
efforts to obtain these. This unfortunate situation suggests the presence of location bias 
within the present work. 
 
Finally, this meta-analysis retains the unavoidable heterogeneity introduced by the failure of 
the included studies to report the results of individual surgical procedures. This is significant 
as the complications likely to occur after procedures performed at various locations along the 
gastrointestinal tract vary greatly, and as such the indiscriminate grouping of these may 
confound the complications reported, and thus the effect attributed to the pharmaconutrition 
interventions provided. 
 
This meta-analysis has highlighted areas for future research. As described above, the 
nutritional aspects of studies on this topic including the reporting of nutritional consumption 
in both groups throughout the study period, and the need for careful selection of control 
formulas are potential confounders in many of the existing published studies. Dietitians are 
largely absent from the authorship of the studies to date, and it seems likely that a more 
multidisciplinary approach to the research in this area is necessary, and is likely to alleviate 
these oversights in future studies. Secondly, convincing data supporting significant economic 
benefit related to the use of pharmaconutrition over standard nutrition products remains 
scarce in the literature. A strong body of evidence supporting the cost-benefit of 
pharmaconutrition is going to be increasingly vital to justify its continued use in healthcare 
environments that are increasing subjected to financial scrutiny in these difficult economic 
times. 
 
CONCLUSIONS: 
While this meta-analysis lends support to the acknowledged beneficial effects of 
pharmaconutrition in the management of elective gastrointestinal surgical patients, it 
highlights the importance of timing of administration as a clinical consideration. Contrary to 
previous findings, preoperative pharmaconutrition failed to deliver any benefit over standard 
formulations when used as a standalone intervention, and the accepted benefits of 
pharmaconutrition (reduction in infectious complications and LOS) were only reported in 
peri- and postoperative administration, and limitations in the LOS data obscure the 
conclusions we can draw on this outcome. It also suggests previously unreported benefits of 
pharmaconutrition with respect to reduced non-infective complications and anastomotic 
dehiscence in postoperative and perioperative administration respectively. Better quality, 
multi-disciplinary intervention and cost-benefit studies are required to further clarify the 
remaining questions on this topic. 
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Figure 1 – PRISMA statement describing the identification, inclusion and exclusion of 
randomized controlled trials evaluating the effect of pharmaconutrition on 
postoperative clinical outcomes compared to standard nutritional provision. 
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Figure 2A – Infectious complications: postoperative administration.  
 
Figure 2B - Infectious complications: perioperative administration. 
 
 
The boxes in Figure 2A and 2B represent individual studies with the size of each 
corresponding to the attributed weighting under a random effects model. Error bars 
represent 95% confidence intervals. The diamond represents the pooled effect size, 
with its length representing the width of the confidence interval. Vertical line 
represents the line of no effect (null hypothesis). 
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Figure 3A – LOS: postoperative administration.  
 
 
Figure 3B- LOS: perioperative administration.  
 
The boxes in Figure 3A and 3B represent individual studies with the size of each 
corresponding to the attributed weighting under a random effects model. Error bars 
represent 95% confidence intervals. The diamond represents the pooled effect size, 
with its length representing the width of the confidence interval. Vertical line 
represents the line of no effect (null hypothesis). 
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Figure 4 – Non-infectious complications: postoperative administration.  
 
The boxes represent individual studies with the size of each corresponding to the 
attributed weighting under a random effects model. Error bars represent 95% 
confidence intervals. The diamond represents the pooled effect size, with its length 
representing the width of the confidence interval. Vertical line represents the line of 
no effect (null hypothesis).
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Figure 5 – Anastomotic dehiscence: perioperative administration.  
 
 
The boxes represent individual studies with the size of each corresponding to the 
attributed weighting under a random effects model. Error bars represent 95% 
confidence intervals. The diamond represents the pooled effect size, with its length 
representing the width of the confidence interval. Vertical line represents the line of 
no effect (null hypothesis). 
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Figure 6 – Funnel plot for LOS: postoperative administration.  
 
 
The points correspond to the treatment effects (log WMD) from 11 individual studies, 
and the diagonal lines show the expected 95% confidence intervals around the pooled 
fixed effect log WMD estimate. 
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Table 1 – Pharmaconutritional Interventions of Included RCTs 
 
Author  
Year 
Timing of 
administration 
Feeding protocol Nutrition goal Pharmaconutrition 
product 
Control product 
McCarter et al  
199812 
Preoperative Oral supplements in addition to normal meals 
for ≥7 days 
 
750mL/d Not stated Not stated 
Braga et al  
20027 
Preoperative Oral supplements in addition to normal diet for 
5 days 
1000mL/d Oral Impact® (Novartis, 
Bern, Switzerland) 
Not stated 
Okamoto et al  
200946 
Preoperative Oral supplements in addition to standard 
hospital diet for 7 days 
750mL/d Impact® (Ajinomoto Pharm 
Co, Japan) 
MEDIF® (Ajinomoto 
Pharm Co, Japan) 
Gunerhan et al 
200915 
Preoperative 7 days, route unspecified Individual 
requirements 
(Harris-Benedict 
Equation) 
 
Impact® (Novartis Nutrition, 
Switzerland) 
Fresubin® (details not 
stated) 
Senkal et al 
 199944 
Perioperative Oral supplements ≥5 days in addition to 
normal hospital diet preoperatively; jejunal 
feeding commenced 12hrs postop continued 
until at least POD5 
 
1000mL/d preop; 
1920mL/d reached 
by POD5 
Impact® (Novartis, Bern, 
Switzerland) 
Not stated 
Braga et al  
19995 
Perioperative Oral supplements for 7 days preoperatively in 
addition to normal food as desired; jejunal 
feeding 6hrs postoperatively and increased to 
goal by POD3. Oral intake from POD7, unclear 
when jejunal feeding ceased. 
 
1000mL/d 
preoperatively; 
1500mL 
postoperatively 
Impact® (Novartis, Bern, 
Switzerland) 
Not stated 
Daly et al  
198847 
Postoperative Jejunal feeding commenced POD1 and 
continued to POD7. Clear fluids until POD7, 
oral intake recommenced POD7. 
individual 
requirements 
(25kcal/kg) 
Nutrisource Modular Diet® 
(Sandoz Nutrition, 
Minneapolis, MN) + 25g L-
Arginine 
Nutrisource Modular 
Diet® (Sandoz Nutrition, 
Minneapolis, MN) + 43g 
L-Glycine 
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Daly et al  
199241 
Postoperative Jejunal feeding commenced POD1 and 
discontinued when patient could meet 
‘adequate’ intake orally.  
 
individual 
requirements 
(25kcal/kg) 
Impact® (Sandoz Nutrition, 
Minneapolis, MN) 
Osmolite HN® (Ross 
Laboratories, 
Columbus, OH) 
Daly et al  
19954 
Postoperative Jejunal feeding commenced from POD1 and 
continued until fluids and foods taken by 
mouth. 
individual 
requirements 
(25kcal/kg) 
Impact® (Sandoz Nutrition, 
Minneapolis, MN) 
Traumacal® (Bristol-
Meyrs Squibb, 
Evansville, IN) 
Schilling et al 
199611 
Postoperative Small bowel feeding commenced ‘as early as 
possible’; Duration of feeding and time to goal 
rate not stated. 
 
individual 
requirements 
(25kcal/kg) 
Impact® (Sandoz Nutrition 
Ltd, Bern, Switzerland) 
Fresubin® (Fresenius 
AG, Stans, Switzerland) 
Senkal et al  
199742 
Postoperative Jejunal feeding commenced 12hrs 
postoperatively. Clear fluids commenced 
between POD5 and POD7. Unclear when 
jejunal feeds ceased. 
 
individual 
requirements 
(25kcal/kg) 
Impact® (Sandoz Nutrition, 
Bern, Switzerland) 
Not stated 
Gianotti et al  
20006 
Postoperative Jejunal feeding commenced 6hrs 
postoperatively and ceased when oral intake 
provided ~800kcal/d. 
 
individual 
requirements 
(25kcal/kg) 
Impact® (Sandoz Nutrition 
Ltd, Bern, Switzerland) 
Not stated 
Jiang et al  
200443 
Postoperative Jejunal feeding commenced POD1 and 
continued until POD7. 
 
individual 
requirements 
(30kcal/kg) 
Stresson Multifibre® 
(Nutricia, Holland) 
Nutrison Multifibre® 
(Nutricia, Holland) 
Chen et al 
200549 
Postoperative Jejunal feeds commenced POD2 postop 
continued to POD9  
 
individual 
requirements 
(30kcal/kg) 
Stresson® (Nutricia China, 
Shanghai, China) 
Nutrison® (Nutricia, 
China, Shanghai, 
China) 
Ferreras et al  
20059 
Postoperative Jejunal feeds commenced 12-18hrs postop 
continued to POD7. 
 
 Impact® (Novartis 
Consumer Health, Spain) 
Isosource Protein® 
(Novartis Consumer 
Health, Spain) 
 
Lobo et al  
201039 
Postoperative Jejunal feeds commenced 4hrs postop 
continued to POD10-15 
 
75mL/hr over 
20hrs/d. 
Stresson® (Nutricia Ltd, 
Netherlands) 
Nutrison High Protein® 
(Nutricia Ltd, 
Netherlands) 
 
Klek et al Postoperative Jejunal feeds commenced 6hrs postop 2400mL/d Reconvan® (Fresenius Peptisorb® (Nutricia Ltd, 
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200813 continued to POD7. 
 
Kabi, Poland) Poland) 
Klek et al  
200814 
Postoperative Jejunal feeds commenced 6hrs postop 
continued to POD7. 
 
2400mL/d Stresson® (Nutricia Ltd) Peptisorb® (Nutricia Ltd, 
Poland) 
Sodergren et al  
201045 
Postoperative Jejunal feeds commenced POD1 and 
continued to POD5, with a possible extension 
period to a maximum of POD15. 
individual 
requirements 
(25kcal/kg) 
Prototype to Intestamin® 
(Fresenius-Kabi, Germany) 
 
Not stated 
Klek et al  
201140 
Postoperative Jejunal feeds commenced 6hr postop and 
continued until POD7. 
~2000mL/d provided 
over 20-22hrs. 
Reconvan® (Fresenius-
Kabi, Poland) 
Peptisorb® (Nutricia, 
Poland) 
POD = Postoperative Day 
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Table 2 – Preoperative Pharmaconutrition study characteristics  
 
Author (year) 
/ Country 
Study 
Population 
Study Design Std 
EN 
(n) 
PhN 
EN 
(n) 
Study Endpoints Source of Funding Mal-
nutrition 
rates 
Jadad 
score 
(R/B/W) 
McCarter et al 
(1998) / USA12 
Gastric, 
esophageal, 
pancreatic Ca 
Std EN vs. high Arg EN 
vs. high Arg/EFAs EN 
11 14 Not stated but appears to be 
immune and clinical 
outcomes 
 
Supported in part by a 
grant from Novartis 
Nutrition Corporation, 
Minneapolis, MN 
 
20% 4 
(1/2/1) 
Braga et al 
 (2002) / Italy7 
Colorectal Ca Preop PhN oral + PhN 
EN postop vs. 
Preop PhN oral vs. 
Preop Std oral vs. 
 no supplementation pre 
op, NBM postop 
 
50 50 Not directly stated. 
Hypotheses involve immune-
metabolic variables, 
morbidity and LOS. 
Products provided by 
Novartis Consumer 
Health , Bern, 
Switzerland 
10% 2 
(2/0/0) 
Okamoto 
(2009)/ 
Japan46 
Gastric Ca PhN EN vs. Std EN 30 30 Postoperative cellular 
immunity; postoperative 
infectious and non-infectious 
complications; SIRS. 
 
N/R N/R 2 
(2/0/0) 
Gunerhan et al 
(2009)/ 
Turkey15 
Unspecified GIT 
Ca 
PhN EN vs. 
Normal diet vs. 
Std EN 
11 13 Nutritional parameters; 
cellular immunity 
N/R 100% 2 
(1/0/1) 
GIT=gastrointestinal; UGI= upper gastrointestinal; Ca = cancer; SIRS = Systemic inflammatory response syndrome; Randomization (out of 2)/Blinding (out of 2)/Withdrawals 
(out of 1); PhN= Pharmaconutrition formulation; Std = standard composition formulation; EN= enteral nutrition; NBM= nil by mouth; N/R= not reported; LOS= length of stay; 
POD = Postoperative Day 
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Table 3 – Perioperative Pharmaconutrition study characteristics 
 
Author (year)/ 
Country 
Study 
Population 
Study Design Std 
EN 
(n) 
PhN 
EN 
(n) 
Study Endpoints Source of Funding Mal-
nutrition 
rates 
Jadad score 
(R/B/W) 
Braga et al 
(1999) / Italy5 
Gastric, 
pancreatic and 
colorectal Ca 
 
PhN EN vs. Std EN 86 85 Reduction of infectious 
complications 
Diets provided by Novartis Nutrition, 
Bern, Switzerland 
23% 5 
(2/2/1) 
Senkal et al 
(1999) / 
Germany44 
UGI and 
pancreatic Ca 
PhN EN vs. Std EN 76 78 Primary outcome: 
Infectious complications 
after POD3 or POD5 
Unclear – 4 organizations are 
thanked (including Nutricia, Bern, 
Switzerland) though reasons not 
stated 
N/R 4 
(1/2/1) 
UGI= upper gastrointestinal; Ca = cancer; R/B/W=Randomization (out of 2)/Blinding (out of 2)/Withdrawals (out of 1); PhN= Pharmaconutrition formulation; Std = standard 
composition formulation; EN= enteral nutrition; TPN= total parenteral nutrition; N/R= not reported; POD = Postoperative Day 
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Table 4 – Postoperative Pharmaconutrtition Study characteristics 
 
Author (year) 
/ Country 
Study 
Population 
Study Design Std 
EN 
(n) 
PhN 
EN 
(n) 
Study Endpoints Source of Funding Mal-
nutrition 
rates 
Jadad 
score 
(R/B/W) 
Daly et al 
(1988) / 
USA47 
UGI, 
pancreatic, 
colorectal Ca 
(97%), 
melanoma 
(3%) 
 
Arginine supplemented Std 
EN  vs. glycine  
supplemented Std EN 
14 16 Not stated, but appears 
to be immune, metabolic 
and clinical outcomes. 
Supported by Georgene S Harmelin 
Surgical Oncology Research Grant, and 
a grant from Sandoz Inc, and NIH Grant 
No 19525. 
 
56% 3 
(1/2/0) 
Daly et al 
(1992) / 
USA41 
UGI, 
pancreatic Ca 
PhN EN vs. Std EN 44 41 Not stated, but appears 
to be nutritional, immune, 
metabolic and clinical 
outcomes. 
Supported by Georgene S Harmelin 
Surgical Oncology Research Grant, and 
a grant from Sandoz Inc, and NIH Grant 
No 19525. 
 
35% 3 
(2/0/1) 
Daly et al 
(1995) / 
USA4 
UGI, 
pancreatic Ca 
PhN EN (inpt ± outpt) vs.  
Std EN (inpt ± outpt)  
 
Only inpatient data was 
used for this analysis 
 
30 30 Clinical outcome, white 
cell fatty acid 
composition, PGE2 
secretion 
Supported by Georgene S Harmelin 
Surgical Oncology Research Fund, 
National institute of Health training grant 
3-T32-CA-09619, and Sandoz Nutrition 
Inc 
30% 3 
(2/0/1) 
Schilling et al 
(1996)/ 
Switzerland11 
 
UGI, 
pancreatic or 
colorectal Ca 
PhN EN vs. Std vs. low 
calorie/ low fat IV solution 
 
14 14 Not stated, but appears 
to be immune function. 
Supported in part by Sandoz Nutrition 
Ltd. 
N/R 2 
(1/0/1) 
Senkal et al 
(1997) / 
Germany42 
 
UGI, 
pancreatic Ca 
PhN EN vs. Std EN 77 77 Not stated, but appears 
to be clinical outcome 
and costs. 
Supported in part by Sandoz Nutrition 
Ltd. 
N/R 5 
(2/2/1) 
Gianotti et al 
(2000) / 
 Italy6 
Pancreatic Ca PhN EN vs. Std EN vs. Std 
TPN 
 
73 71 Not stated, but appears 
to be immunometabolic 
parameters and clinical 
outcome 
Partially supported by Novartis Nutrition, 
Bern, Switzerland 
60% 2 
(2/0/0) 
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Jiang et al 
(2004) / 
China43 
UGI, colorectal 
Ca (81%), 
other Ca (7%), 
other diseases 
(12%) 
PhN EN vs. Std EN 60 60 Not stated, but appear to 
be immune function, 
inflammatory response, 
and infectious 
complications 
 
None stated N/R 2 
(1/0/1) 
 
Chen et al 
(2005) / 
China49 
 
Gastric Ca 
 
PhN EN vs. Std EN 
 
20 
 
20 
 
Inflammatory and 
immunological 
parameters 
 
 
N/R 
 
N/R 
 
1 
(1/0/0) 
Ferreras et al 
(2005) / Spain9 
Gastric Ca PhN EN vs. Std EN 30 30 Primary: Postop wound 
healing 
Secondary: Infectious 
complications; morbidity, 
LOS. 
 
Supported in part by Novartis Consumer 
Health, Spain 
20% 5 
(2/2/1) 
Lobo et al 
(2006) / UK39 
UGI Ca PhN EN vs. Std EN 54 54 Primary: infectious 
complications. 
Secondary: non-infective 
complications; mortality; 
LOS. 
Dr Lobo: Research Fellowship from 
Special Trustees of the University 
Hospital, Queen’s Medical Centre, 
Nottingham. Dr Crowe: grant from 
Nutricia Clinical Care, UK. Feeds 
provided gratis by Nutricia Clinical Care, 
UK. 
States funding sources were not involved 
in the design or execution of the study or 
in the publication of the work. 
 
N/R 5 
(2/2/1) 
Klek et al 
 (2008) / 
Poland13 
Gastric, 
pancreatic Ca 
PhN EN vs. Std EN 91 92 Postoperative 
complications; LOS; 
liver/kidney/immune 
function; treatment 
tolerance. 
 
Conflict of interest denied; funding source 
N/R 
9% 3 
(2/0/1) 
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Klek et al 
(2008) / 
Poland14 
Gastric, 
pancreatic Ca 
PhN EN vs. Std EN vs. 
PhN TPN vs. Std TPN 
53 52 Infectious complications 
in well nourished patients 
 
N/R 16% 3 
(2/0/1) 
 
Sodergren et 
al (2010) / 
UK45 
 
UGI surgery 
(96%), 
Other (4%) 
 
PhN EN vs. Std EN 
 
21 
 
23 
 
Primary: C-Reactive 
Protein, prealbumin, 
retinol binding protein. 
Secondary: clinical, 
infections, safety, 
tolerance, biochemical 
 
 
Fresenius Kabi Clinical Research 
Department (Bad Homberg, Germany) – 
actively involved in the randomization 
process. 
 
N/R 
 
3 
(2/1/0) 
Klek et al 
(2011) / 
Poland40 
Gastric, 
pancreatic Ca 
PhN EN vs. Std EN 153 152 Primary: postop 
complications 
Secondary: LOS, 
immune function, liver 
and kidney function 
Conflict of interest denied; funding source 
N/R 
100% 3 
(2/0/1) 
States 
blinding in 
title but 
none 
described 
UGI= upper gastrointestinal; Ca = cancer; SIRS = Systemic inflammatory response syndrome; inpt= inpatient; outpt= outpatient 
Randomization (out of 2)/Blinding (out of 2)/Withdrawals (out of 1); PhN = Pharmaconutrition formulation; Std = standard composition formulation; EN= enteral nutrition; TPN= 
total parenteral nutrition; NBM= nil by mouth; N/R= not reported; LOS= length of stay; POD = Postoperative Day;  
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Table 5 – Pharmaconutrition products utilized within included studies 
 
Product  Energy (per L) Protein (per L) Pharmaconutrients (per L) 
Oral Impact® 1010kCal 56g 12.5g Arginine, 
3.3 omega-3 fatty acid, RNA 
quantity not stated 
 
Impact® 1000kCal 
or 
1015kcal 
56g 
or 
59g 
12.5g Arginine, 
3.3 omega-3 fatty acid, 
1.2g  RNA 
 
Nutrisource Modular Diet® 
+ 25g L-Arginine 
 
1090kCal 45g 25g additional Arginine 
Stresson Multifibre® 
or 
Stresson® 
1250kcal 75g 8.9g Arginine 
13g Glycine 
Omega-6:omega-3 ratio 3.45:1 
 
Reconvan® 1000kcal 55g Not stated 
 
Prototype to Intestamin® n/s n/s arginine, glutamine, omega 3, 
tributyrin, Vitamins C, E, B-
carotene and micronutrients 
n/s = not stated 
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Table 6 – Standard nutrition products utilized within included studies 
 
Product  Energy (per L) Protein (per L) 
MEDIF® 
 
Isocaloric isonitrogenous 
Fresubin® 
 
1000kcal 38g 
Nutrisource Modular Diet®  + 
43g L-Glycine 
 
1090kCal 45g 
Osmolite HN® 
 
1070kcal 45g 
Traumacal® 
 
1115kcal 62g 
Nutrison Multifibre® 
 
1000kcal 40g 
Nutrison® 
 
1000kcal 40g 
Isosource Protein® 
 
1220kcal 66g 
Nutrison High Protein® 
 
1250kcal 75g 
Peptisorb® 1000kcal 40g 
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Table 7: Summary of pooled data of Preoperative Pharmaconutrition versus Standard Nutrition 
 
 
 
 
 
 
 
 
Outcome Variables Pooled OR 
WMD (95% CI) 
 
Test for overall effect Test for heterogeneity 
  Z p value Q p value I2 index 
Mortality 1.21 (0.22;  6.64) 0.22 0.82 0.27 0.99 0% [0%; 0%] 
 
Infective complications 
 
0.56  (0.22; 1.47) -1.17 0.24 7.2 0.12 44.5% [0%; 79.6%] 
 
Anastomotic dehiscence 
 
0.79 (0.30; 2.08) 
 
-0.47 
 
0.64 2.2 
 
0.53 0% [0%; 79.1%] 
Non-infective 
complications 
 
1.97 (0.78; 4.94) 1.44 0.15 0.49 0.97 0% [0%; 0%] 
Length of stay 1.21 (-2.31; 4.74) 0.67 0.50 28.47 
 
<0.01 
 
89.5% [75.8%; 95.4%] 
Intolerance symptoms 0.66 (0.30; 1.44) 
 
-1.04 0.30 1.92 0.38 0% [0%; 89.2%] 
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Table 8: Summary of pooled data of Perioperative Pharmaconutrition versus Standard Nutrition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   Outcome Variables Pooled OR 
WMD (95% CI) 
 
Test for overall effect Test for heterogeneity 
  Z p value Q p value I2 index 
Mortality 0.51 (0.04;  6.17) -0.53 0.60 0.17 0.68 0% 
 
Infective complications 
 
0.44  (0.24; 0.81) -2.62 0.00 0.67 0.41 0% 
Anastomotic dehiscence 
 
0.39 (0.17; 0.93) 
 
-2.13 
 
0.03 0.27 
 
0.60 
 
0% 
Non-infective 
Complications 
 
0.79 (0.29; 2.17) -0.45 0.65 0.34 0.56 0% 
Length of stay -2.57 (-3.70; -1.44) -3.02 0.00 3.68 
 
0.05 
 
72.9% 
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Table 9: Summary of pooled data of Postoperative Pharmaconutrition versus Standard Nutrition 
 
 
Outcome Variables Pooled OR 
WMD (95% CI) 
 
  Test for overall effect Test for heterogeneity 
  Z p value Q p value I2 index 
Mortality 0.85 (0.45; 1.59) -0.51 0.61 6.04 0.95 0% [0%; 3.3%] 
 
Infective complications  
0.61  (0.47; 0.79) 
 
-3.80 
 
<0.01 
11.81 
 
0.54 0% [0%; 50.5%] 
 
Anastomotic dehiscence 
 
0.72 (0.37; 1.40) 
 
 
-0.96 
 
 
0.34 
0.73 
 
0.99 
 
0% [0%; 0%] 
 
Non-infective 
complications 
 
0.70  (0.52; 0.94) 
 
-2.38 
 
0.02 
6.12 0.80 0% [0%; 35%] 
 
Length of stay 
 
-2.30 (-3.71; -0.89) 
 
-3.20 
0.00 69.71 
 
<0.01 
 
85.7% [76.1%; 91.4%] 
 
Gastrointestinal 
intolerance symptoms 
 
0.69 (0.44; 1.08) 
 
-1.63 
 
0.10 
 
2.7 
 
0.61 
 
0% [0%; 69.2%] 
